| Year |
Citation |
Score |
| 2024 |
Price MJ, Nguyen AD, Haines C, Baëta CD, Byemerwa J, Murkajee D, Artham S, Kumar V, Lavau C, Wardell S, Varghese S, Goodwin CR. UDP-6-glucose dehydrogenase in hormonally responsive breast cancers. Biorxiv : the Preprint Server For Biology. PMID 38562874 DOI: 10.1101/2024.03.20.585919 |
0.412 |
|
| 2021 |
Haines CN, Wardell SE, McDonnell DP. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays in Biochemistry. PMID 34328178 DOI: 10.1042/EBC20200174 |
0.478 |
|
| 2021 |
McDonnell DP, Wardell SE, Chang CY, Norris JD. Next-Generation Endocrine Therapies for Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003565. PMID 33705209 DOI: 10.1200/JCO.20.03565 |
0.325 |
|
| 2020 |
Andreano KJ, Baker JG, Park S, Safi R, Artham S, Oesterreich S, Jeselsohn R, Brown M, Sammons S, Wardell SE, Chang CY, Norris JD, McDonnell DP. The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor. Molecular Cancer Therapeutics. PMID 32381587 DOI: 10.1158/1535-7163.Mct-19-1148 |
0.528 |
|
| 2020 |
Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. PMID 32130619 DOI: 10.1007/S10549-020-05575-9 |
0.536 |
|
| 2019 |
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. Breast Cancer Research and Treatment. PMID 31734822 DOI: 10.1007/s10549-019-05498-0 |
0.304 |
|
| 2019 |
Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, et al. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Reports. 29: 889-903.e10. PMID 31644911 DOI: 10.1016/J.Celrep.2019.09.032 |
0.485 |
|
| 2019 |
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. Breast Cancer Research and Treatment. PMID 31562570 DOI: 10.1007/S10549-019-05454-Y |
0.535 |
|
| 2019 |
Manzari MT, Anderson GR, Lin KH, Soderquist RS, Çakir M, Zhang M, Moore CE, Skelton RN, Fèvre M, Li X, Bellucci JJ, Wardell SE, Costa SA, Wood KC, Chilkoti A. Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models. Science Advances. 5: eaaw9162. PMID 31517048 DOI: 10.1126/Sciadv.Aaw9162 |
0.439 |
|
| 2019 |
Wardell SE, Norris JD, McDonnell DP. Targeting mutant estrogen receptors. Elife. 8. PMID 30648967 DOI: 10.7554/Elife.44181 |
0.512 |
|
| 2019 |
Sammons S, Anderson G, Wardell S, McDonnell DP, Marcom PK, Wood K. Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer. Journal of Clinical Oncology. 37: e14653-e14653. DOI: 10.1200/Jco.2019.37.15_Suppl.E14653 |
0.483 |
|
| 2018 |
Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal B K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, ... ... Wardell S, et al. Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer. Cancer Discovery. PMID 29991605 DOI: 10.1158/2159-8290.Cd-17-1229 |
0.56 |
|
| 2018 |
Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP, Wood KC. Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. Nature Communications. 9: 1677. PMID 29700304 DOI: 10.1038/S41467-018-04033-X |
0.308 |
|
| 2018 |
Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, ... ... Wardell S, et al. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER alphaWTand ER alphaMUTBreast Cancer. Cancer Discovery. 8: 1176-1193. DOI: 10.2210/Pdb6Chw/Pdb |
0.481 |
|
| 2018 |
Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov A, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, et al. Abstract 5496: A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product Cancer Research. 78: 5496-5496. DOI: 10.1158/1538-7445.Am2018-5496 |
0.407 |
|
| 2018 |
Yao Z, Wardell S, Spasojevic I, Norris J, Katzenellenbogen J, McDonnell D, Josan JS. Abstract 1805: Development of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer Cancer Research. 78: 1805-1805. DOI: 10.1158/1538-7445.Am2018-1805 |
0.475 |
|
| 2017 |
McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. The Prostate. PMID 29243324 DOI: 10.1002/Pros.23467 |
0.414 |
|
| 2017 |
Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, Sullivan PM, Kemper JK, Gunn MD, McDonnell DP, Nelson ER. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nature Communications. 8: 864. PMID 29021522 DOI: 10.1038/S41467-017-00910-Z |
0.396 |
|
| 2017 |
Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov AA, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, et al. A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metabolism. PMID 28918937 DOI: 10.1016/J.Cmet.2017.08.017 |
0.35 |
|
| 2017 |
Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, et al. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports. 20: 999-1015. PMID 28746882 DOI: 10.1016/J.Celrep.2017.07.006 |
0.403 |
|
| 2017 |
Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT. Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene. PMID 28604749 DOI: 10.1038/Onc.2017.192 |
0.394 |
|
| 2017 |
Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, et al. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. The Journal of Clinical Investigation. PMID 28463227 DOI: 10.1172/Jci87328 |
0.428 |
|
| 2017 |
Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP. CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. Molecular Cancer Research : McR. PMID 28209757 DOI: 10.1158/1541-7786.Mcr-17-0028 |
0.434 |
|
| 2017 |
McDonnell D, Cocce K, Wardell S, Norris J. Abstract IA30: Targeting hormone receptors for degradation: Nuclear receptor downregulation as a therapeutic approach in cancer Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Ia30 |
0.562 |
|
| 2017 |
Wardell SE, Yllanes AP, Baker JG, Baldi RM, Krebs TK, Sorrentino J, Bisi J, Strum J, Norris JD. Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer Cancer Research. 77: 5641-5641. DOI: 10.1158/1538-7445.Am2017-5641 |
0.549 |
|
| 2017 |
Wardell SE, Yllanes AP, Norris JD, Stice JP, White H, Fleming RA, Strum JC, Moore WR, McDonnell DP. Abstract 1588: Effects of the selective CYP17-lyase and androgen receptor (AR) inhibitor, seviteronel, and the cyclin-dependent kinase (CDK) 4/6 inhibitor, G1T38, on tumor growth in an AR-V7+ castration-resistant prostate cancer (CRPC) xenograft model Cancer Research. 77: 1588-1588. DOI: 10.1158/1538-7445.Am2017-1588 |
0.455 |
|
| 2016 |
Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Science Translational Medicine. 8: 369ra175. PMID 27974663 DOI: 10.1126/Scitranslmed.Aae0348 |
0.476 |
|
| 2016 |
Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT. Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene. PMID 27869167 DOI: 10.1038/onc.2016.394 |
0.378 |
|
| 2016 |
Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, Chao CA, Lawrence SA, Stice JP, Spasojevic I, Baker JG, Kim SH, McDonnell DP, Katzenellenbogen JA, Norris JD. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nature Chemical Biology. PMID 27501397 DOI: 10.1038/Nchembio.2131 |
0.471 |
|
| 2016 |
Ellison S, Norris J, Wardell S, Eisner J, Hoekstra W, Stagg D, Alley H, Moore W, McDonnell D. Abstract P3-14-04: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-14-04 |
0.553 |
|
| 2016 |
Stice JP, White HS, Wardell SE, Yllanes AY, Lawrence SA, Alley H, McDonnell DP, Strum JC. Abstract 2820: Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer Cancer Research. 76: 2820-2820. DOI: 10.1158/1538-7445.Am2016-2820 |
0.448 |
|
| 2015 |
Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocrine-Related Cancer. 22: 713-24. PMID 26162914 DOI: 10.1530/Erc-15-0287 |
0.552 |
|
| 2015 |
McDonnell DP, Wardell SE, Norris JD. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. Journal of Medicinal Chemistry. 58: 4883-7. PMID 26039356 DOI: 10.1021/Acs.Jmedchem.5B00760 |
0.539 |
|
| 2015 |
Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder RJ, Lai JP, Norris JD, McDonnell DP, Li S. Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy resistant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25991817 DOI: 10.1158/1078-0432.Ccr-15-0360 |
0.551 |
|
| 2015 |
Moore WR, Norris JD, Wardell S, Eisner JR, Hoekstra WJ, Schotzinger RJ, McDonnell DP. Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model. Journal of Clinical Oncology. 33: 263-263. DOI: 10.1200/Jco.2015.33.7_Suppl.263 |
0.397 |
|
| 2015 |
Nelson ER, Wardell SE, McDonnell DP. Abstract A82: The cholesterol metabolite, 27-hydroxycholesterol, promotes breast cancer metastasis Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A82 |
0.494 |
|
| 2014 |
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Science Signaling. 7: ra121. PMID 25538079 DOI: 10.1126/Scisignal.Aaa1877 |
0.465 |
|
| 2014 |
Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. Molecular Cancer Research : McR. 12: 1829-39. PMID 25100862 DOI: 10.1158/1541-7786.Mcr-14-0195 |
0.528 |
|
| 2014 |
Wardell SE, Nelson ER, McDonnell DP. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). Steroids. 90: 30-8. PMID 25084324 DOI: 10.1016/J.Steroids.2014.07.013 |
0.453 |
|
| 2014 |
McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR, Nelson ER. Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Research. 74: 4976-82. PMID 25060521 DOI: 10.1158/0008-5472.Can-14-1756 |
0.448 |
|
| 2013 |
Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science (New York, N.Y.). 342: 1094-8. PMID 24288332 DOI: 10.1126/Science.1241908 |
0.488 |
|
| 2013 |
Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2420-31. PMID 23536434 DOI: 10.1158/1078-0432.Ccr-12-3771 |
0.523 |
|
| 2013 |
Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone. 53: 42-50. PMID 23168292 DOI: 10.1016/J.Bone.2012.11.011 |
0.39 |
|
| 2013 |
Nelson ER, Wardell SE, Howe MK, Carver NJ, Umetani M, McDonnell DP. Abstract PR3: The cholesterol metabolite 27-hydroxycholesterol increases breast cancer tumor growth and metastasis Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-Pr3 |
0.484 |
|
| 2013 |
Wright TM, Wardell SE, Nelson ER, McDonnell DP. Abstract A96: The role of the proto-oncogene AGR2 in endocrine resistant breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A96 |
0.521 |
|
| 2013 |
Wardell SE, McDonnell DP, Nelson ER. Regulation of Bone Cell Function by Estrogens Osteoporosis: Fourth Edition. 329-344. DOI: 10.1016/B978-0-12-415853-5.00014-5 |
0.373 |
|
| 2012 |
Wardell SE, Kazmin D, McDonnell DP. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Molecular Endocrinology (Baltimore, Md.). 26: 1235-48. PMID 22570330 DOI: 10.1210/Me.2012-1031 |
0.524 |
|
| 2011 |
Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochemical Pharmacology. 82: 122-30. PMID 21501600 DOI: 10.1016/J.Bcp.2011.03.031 |
0.57 |
|
| 2010 |
McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Current Opinion in Pharmacology. 10: 620-8. PMID 20926342 DOI: 10.1016/J.Coph.2010.09.007 |
0.521 |
|
| 2010 |
Wardell SE, Narayanan R, Weigel NL, Edwards DP. Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Molecular Endocrinology (Baltimore, Md.). 24: 335-45. PMID 20008003 DOI: 10.1210/Me.2008-0081 |
0.572 |
|
| 2009 |
Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, McDonnell DP. Glucose metabolism as a target of histone deacetylase inhibitors. Molecular Endocrinology (Baltimore, Md.). 23: 388-401. PMID 19106193 DOI: 10.1210/Jcem.94.2.9997 |
0.305 |
|
| 2006 |
Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacological Reviews. 58: 782-97. PMID 17132855 DOI: 10.1124/Pr.58.4.9 |
0.397 |
|
| 2005 |
Wardell SE, Kwok SC, Sherman L, Hodges RS, Edwards DP. Regulation of the amino-terminal transcription activation domain of progesterone receptor by a cofactor-induced protein folding mechanism. Molecular and Cellular Biology. 25: 8792-808. PMID 16199860 DOI: 10.1128/Mcb.25.20.8792-8808.2005 |
0.52 |
|
| 2005 |
Wardell SE, Edwards DP. Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). Seminars in Reproductive Medicine. 23: 9-21. PMID 15714386 DOI: 10.1055/S-2005-864030 |
0.596 |
|
| 2002 |
Edwards DP, Wardell SE, Boonyaratanakornkit V. Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. The Journal of Steroid Biochemistry and Molecular Biology. 83: 173-86. PMID 12650714 DOI: 10.1016/S0960-0760(02)00265-0 |
0.562 |
|
| 2002 |
Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP. Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Molecular and Cellular Biology. 22: 5451-66. PMID 12101239 DOI: 10.1128/Mcb.22.15.5451-5466.2002 |
0.561 |
|
| Show low-probability matches. |